Navigation Links
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Date:3/25/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, March 25, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin* was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of type 2 diabetes mellitus (T2D) in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

"We are excited to have submitted an application for a potential new treatment option that may help patients better manage their type 2 diabetes mellitus," said Christophe Arbet-Engels , MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim. "Type 2 diabetes mellitus is a critical health issue facing the world today, and through the Boehringer Ingelheim and Lilly Diabetes Alliance, we are committed to developing new treatments to address patients with this disease."

Empagliflozin is being investigated in adults with T2D in a Phase III clinical trial program that plans to enroll more than 14,500 patients.[1] In total, this program comprises 12 multinational clinical trials, including a large cardiovascular outcome trial. Boehringer Ingelheim and Lilly plan to present detailed data disclosures for many of these studies at scientific medical meetings and in publications in 2013 and 2014.

About Diabetes 
Approximately 25.8 million Americans[2] and an estimated 371 million people worldwide[3] have type 1 or ty
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
2. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
3. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
4. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
5. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
6. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
7. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
8. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Boehringer Ingelheim Announces Equine Research Awards
11. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... 21, 2011 MicroAire Surgical Instruments ... for carpal tunnel syndrome.  MicroAire,s new device, called ... assembly that allows surgeons to treat carpal tunnel ... wrist – thereby avoiding full open-hand surgery through ...
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
Cached Medicine Technology:MicroAire Introduces New SlimLine™ ECTR Cannula 2
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... FDA-approved device has been shown to reduce seizures in ... percent. When coupled with an innovative electrode placement planning ... the complete elimination of seizures in nearly half of ... trials. , That,s good news for a large portion ... with epilepsy whose seizures can,t be controlled with medications ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... Community Unites Behind Extraordinary Global Effort, ... SAN FRANCISCO, July 23 The Medpedia ... largest collaborative online,encyclopedia of medicine called Medpedia. ... health professionals are now,volunteering to collaboratively build ...
... treatment and prognosis may be affected, study says , , ... or pancreatic cancer may have more lymph nodes examined ... designated comprehensive cancer centers or at hospitals that do ... study. , If too few lymph nodes are examined ...
... international scientific and professional organization of more than ... technology and science of molecular imaging and nuclear ... nuclear medicine and molecular imaging research. The awards, ... announced at SNM,s 55th Annual Meeting, held in ...
... program saves time, reduces costs and increases safety; $1000 incentive may ... ... Chapel Hill, NC (PRWEB) July 22, 2008 -- Imagine a health ... prescription into a PDA or computer, and getting immediate feedback about ...
... head and neck cancer, accurately determining how advanced the cancer ... until now. New Saint Louis University research has found ... tool to detect secondary cancers, which occur in 5 to ... study findings, which will be presented on Tuesday, July 22 ...
... body, they could lead to nonsurgical treatments , , TUESDAY, July ... valuable in efforts to develop nonsurgical treatments for spinal cord ... and Sweden. , They say it may be possible to ... to repair damaged nerve cells. , An adult,s spinal cord ...
Cached Medicine News:Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 2Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 3Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 4Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 5Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 6Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 7Health News:Medpedia Announced, World's Largest Collaborative Online Encyclopedia of Medicine and Health 8Health News:More Cancer Lymph Nodes Analyzed at Specialty Centers 2Health News:Seeding the future: SNM grants grow molecular imaging and nuclear medicine research 2Health News:Seeding the future: SNM grants grow molecular imaging and nuclear medicine research 3Health News:BCBSNC Makes Electronic Prescribing Available Statewide 2Health News:BCBSNC Makes Electronic Prescribing Available Statewide 3Health News:BCBSNC Makes Electronic Prescribing Available Statewide 4Health News:Has cancer spread? Research identifies best way to find answers so treatment can begin 2Health News:Spinal Cord Stem Cells May Act as Nerve Repair System 2
... time-consuming tasks and delivers consistently ... productivity and ensure testing accuracy ... offers automated reticulocyte counts and ... excellent sensitivity, specificity and efficiency ...
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... bi-polar CryoCor CryoBlator Series of Cryoablation Catheters ... catheter design with the two-stage cooling system ... maximize the delivery of cryoenergy to the ... work together to create the transmural lesions ...
... 5 software, the latest from Quality ... management application designed specifically for implementing ... system. The superior design, functionality, security, ... tool for managing a quality program., ...
Medicine Products: